BI 3822971 / Boehringer Ingelheim - LARVOL DELTA

A Study to Test How Well Different Doses of BI 3822971 Are Tolerated by People With Advanced Cancer (Solid Tumours) (clinicaltrials.gov) - P1 | N=137 | Not yet recruiting | Sponsor: Boehringer Ingelheim

First-in-human • New P1 trial • Breast Cancer • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer